Universal Opt-Out Hepatitis C Virus Testing and Treatment on Entry in California State Prisons

This study demonstrates that universal opt-out hepatitis C virus testing and treatment upon entry into California state prisons between 2016 and 2023 successfully identified a large number of infections and facilitated equitable access to direct-acting antiviral treatment, particularly for individuals with substance use disorders.

The Gist

Imagine California's state prisons as a massive, high-traffic airport terminal. Every day, thousands of people ("entrants") arrive at this terminal. In the past, if someone arrived with a hidden, silent virus called Hepatitis C, they might have flown through the system without anyone noticing, eventually landing back in the general population and spreading the virus further.

This paper is a report card on a new, bold policy the airport (California prisons) implemented starting in 2016 to catch that virus before it could spread.

Here is the story of what they did, what they found, and why it matters, explained in simple terms.

The New Policy: "The Universal Security Check"

Before 2016, testing for Hepatitis C in prisons was hit-or-miss. It was like only checking the luggage of people who looked suspicious.

In July 2016, California changed the rules. They decided to run a universal, opt-out security check on everyone entering the prison.

• Opt-out: This means everyone gets tested automatically. If you don't want to be tested, you have to actively say "no." Most people just go along with it.
• The Goal: To find the virus early, treat it, and stop it from spreading, aiming to eventually eliminate Hepatitis C entirely.

The Results: Catching the Invisible

The researchers looked at data from over 176,000 people who entered the prison between 2016 and 2023. Here is what they found:

1. The Check-Up Rate: They successfully tested about 76% of everyone who walked in. That's a huge improvement over the old days.
2. The Discovery: Of the people tested, about 1 in 5 had ever been infected with Hepatitis C.
3. The Active Cases: About 13% of all new arrivals were currently carrying the virus (meaning it was still active in their bodies).
   • Analogy: Imagine a bus full of 100 people. In the general population, maybe 1 or 2 people have this virus. In this prison bus, about 13 people had it. This proves that prisons are a critical place to find and fix the problem.

The Treatment: The "Cure" Train

Finding the virus is only step one. The next step is giving them the medicine (called Direct-Acting Antivirals, or DAAs) that can cure the infection.

• The Progress: At the very beginning of the program, very few people got the medicine. But as the years went on, the system got better at connecting patients to doctors.
• The Success: By the end of the study period, 76% of the people who were found to have the active virus started their treatment within a year.
• The Speed: For those who got treated, half of them started the "cure train" within just six months of being tested.

The "Substance Use" Connection

One of the most interesting parts of the story involves people struggling with substance use disorders (SUD), like addiction to opioids or other drugs.

• The Reality: People with identified substance use issues were much more likely to have Hepatitis C (about 3 times more likely than those without).
• The Good News: Because the prison system started linking Hepatitis C treatment with substance use treatment, these high-risk individuals were actually more likely to get the cure than others.
• Analogy: Think of it like a hospital that treats a broken leg and a bad cough at the same time. By treating the addiction and the virus together, they made sure the people who needed the cure the most actually got it.

The Bumps in the Road

The study wasn't a perfectly straight line up.

• The Pandemic Dip: In 2020 and 2021, the numbers dropped. Why? The COVID-19 pandemic hit the prison system hard. It was like a storm grounding all the flights; testing and treatment slowed down because the system was overwhelmed with a different emergency.
• The Recovery: Once things stabilized, the numbers bounced back up, showing the system is resilient.

Why This Matters (The Big Picture)

This paper is a victory lap for a specific strategy: Universal Screening.

The authors argue that because the virus is so common in prisons (13% vs 1% in the general public), you cannot just wait for people to ask for a test. You have to check everyone.

By treating people while they are inside, California is doing two things:

1. Saving Lives: Giving people a cure for a disease that used to be a death sentence.
2. Stopping the Spread: When these people are released back into society, they aren't carrying the virus with them anymore. It's like fixing a leak in a boat before it sinks the whole ship.

In a nutshell: California prisons turned into a giant, efficient clinic that caught a hidden virus, treated thousands of people, and proved that even in a high-stress environment like a prison, you can provide fair, effective healthcare to everyone, especially those who are often overlooked.

Technical Summary

1. Problem Statement

Hepatitis C virus (HCV) infection rates in correctional facilities are significantly higher than in the general U.S. population (estimated at 8.7% in state prisons vs. 1.6% nationally). Prisons represent a critical, high-yield venue for HCV elimination efforts due to the concentration of infected individuals and the opportunity for controlled, systematic screening and treatment. However, prior to 2016, testing and treatment access in California state prisons was inconsistent. The study addresses the need to evaluate the effectiveness of a comprehensive, universal opt-out testing and treatment strategy implemented by the California Correctional Health Care Services (CCHCS) to determine if it successfully increased testing coverage, identified active infections, and facilitated treatment initiation across diverse demographic groups.

2. Methodology

• Study Design: A retrospective cohort analysis of individual-level electronic health record (EHR) data.
• Population: All adults entering California state prisons ("entrants") between July 1, 2016, and June 30, 2023.
  • Inclusion Criteria: Adults with at least six months of follow-up data while incarcerated.
  • Total Cohort: 176,967 individuals.
• Intervention: Implementation of universal opt-out HCV antibody testing within four weeks of entry, followed by confirmatory RNA testing for antibody-positive individuals and linkage to Direct-Acting Antiviral (DAA) treatment.
• Key Metrics: The study quantified four sequential outcomes:
  1. Testing Coverage: Percentage of entrants receiving an HCV antibody test within 4 weeks of entry.
  2. Seroprevalence: Percentage of tested individuals who were antibody-positive (indicating ever infected).
  3. Active Infection: Percentage of antibody-positive individuals who were RNA-positive (indicating current infection).
  4. Treatment Initiation: Percentage of RNA-positive individuals who started DAA treatment within one year of entry.
• Stratification: Outcomes were analyzed by fiscal year, sex, age group, race/ethnicity, prior incarceration history, anticipated sentence length, and Substance Use Disorder (SUD) status.
• Ethics: Determined non-human subjects research by Stanford University IRB.

3. Key Contributions

• Comprehensive Real-World Evidence: Provides one of the largest and most detailed evaluations of a state-wide prison HCV elimination program, covering a 7-year period during the rollout of universal screening.
• Equity Analysis: Demonstrates that high-coverage testing and treatment can be achieved equitably across diverse demographic subgroups (race, age, sex), despite variations in infection prevalence.
• SUD Integration: Specifically highlights the intersection of HCV and Substance Use Disorder, showing that integrated care models significantly improve treatment initiation rates for high-risk populations.
• Policy Benchmarking: Establishes a model for how correctional systems can serve as a primary engine for national HCV elimination goals.

4. Key Results

Overall Outcomes (July 2016 – June 2023):

• Testing: 133,639 entrants (76%) were tested for HCV antibody.
• Infection Rates:
  • 25,455 (19% of those tested) were antibody-positive (ever infected).
  • 16,738 (66% of antibody-positive) were RNA-positive (currently infected).
  • This translates to a 13% current infection rate among all entrants.
• Treatment: 7,479 individuals (45% of those currently infected) initiated DAA treatment within one year.
  • 51% of those treated started within six months of their positive test.

Temporal Trends:

• Testing: Increased from 80% (FY 2017-18) to 92% (FY 2022-23).
• Treatment Initiation: Increased dramatically from 20% to 76% over the same period.
• RNA Positivity: Decreased from 72% to 55% among antibody-positive individuals, suggesting successful treatment of prior cohorts or changes in the incoming population.
• Pandemic Impact: A temporary decline in testing and treatment was observed in 2020–2021, attributed to COVID-19 disruptions.

Demographic and Risk Stratification:

• SUD Status: Individuals with identified SUD had 3.2 times higher antibody positivity rates compared to those without. Crucially, they also had 1.3 times higher rates of initiating DAA treatment (57.9% vs. 44.1% for those screened negative/no SUD identified).
• Prevalence by Group: Current infection rates were highest among:
  • Age: Older entrants (50+ years: 32.3% antibody positive).
  • Race/Ethnicity: Hispanic (19.7%) and Non-Hispanic White (31.1%) entrants.
  • History: Those previously incarcerated in a California prison (28.4% antibody positive).
• Equity: Despite these prevalence differences, the access to testing and treatment initiation remained relatively consistent across demographic groups.

5. Significance and Discussion

• Validation of Universal Screening: The study confirms that universal opt-out testing in prisons is a highly effective strategy for identifying a large burden of undiagnosed HCV, particularly in populations with high SUD prevalence.
• Treatment as Prevention: The high rate of treatment initiation (45% overall, rising to 76% in recent years) demonstrates that prisons can successfully transition from diagnosis to cure, a critical step in breaking transmission chains.
• SUD Synergy: The finding that individuals with SUD were more likely to be treated underscores the value of integrating HCV care with substance use treatment programs.
• Limitations: The authors note that results may not be generalizable to other states due to differences in prison demographics, sentence lengths, and health system infrastructure. Additionally, the study relies on administrative data which may have coding limitations.
• Conclusion: The CCHCS model proves that correctional facilities are central to national HCV elimination efforts. By achieving equitable access to care and effectively targeting high-risk groups (particularly those with SUD), the program has created a scalable framework for reducing the HCV burden in the United States.